Glucagon-like peptide-1 (GLP-1) receptor agonists, the active ingredient in weight-loss drugs such as tirzepatide and semaglutide, promote satiation even before a person begins his or her meal, a new study suggests.
The findings, published in Science last month, indicate that the drug influences a brain pathway in the hypothalamus, causing a person to feel full when he or she encounters food.
